Clinical Trials Browser

Active not recruiting × Interventional × Leukemia, Prolymphocytic × Clear all

NCT01589302 2026-04-13

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

Phase 2 Active not recruiting

154 enrolled 18 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT02029443 2026-02-06

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Phase 1/2 Active not recruiting

306 enrolled 26 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT06001385 2026-02-05

OPTIMIZE

Phase 2 Active not recruiting

313 enrolled

LymphoidMyeloidOther hematologic neoplasmOther neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Leukemia, Myeloid, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT02007044 2025-11-06

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Phase 2 Active not recruiting

66 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic